Atacicept: ORIGIN proteinuria evidence and eGFR confirmation

Vera ownership and approval scope

Atacicept is Vera Therapeutics' program, not Vertex's. Vera's filing records accelerated approval of TRUTAKNA on July 7, 2026 to reduce proteinuria in adults with primary IgA nephropathy at risk of progression. The pending ORIGIN 3 analysis addresses kidney-function evidence potentially supporting full approval; it is not another initial proteinuria readout. Analytical judgment: accelerated approval and confirmation of long-term benefit are related but distinct evidentiary steps. A reduction in urinary protein is relevant to disease risk, yet the direct question is whether filtration declines more slowly. Correct company attribution is essential because financing, trial execution and regulatory commitments belong to Vera. The July authorization must not be attributed to an unrelated ticker simply because other companies have competing immune-nephrology programs. [1] [5]

BAFF, APRIL and pathogenic immunoglobulin

Atacicept is a soluble TACI-based fusion protein that binds BAFF and APRIL, survival signals involved in B-cell and antibody biology. In IgA nephropathy, reducing pathogenic galactose-deficient IgA1 is intended to interrupt an upstream driver of immune-complex injury. Analytical judgment: this differs from simply changing glomerular hemodynamics, but mechanisms can converge on the same proteinuria endpoint. A fall in IgA-related biomarkers strengthens evidence of target action without directly proving preserved nephron function. The full causal chain should show immunologic change, proteinuria improvement and a credible eGFR trajectory. Background renin–angiotensin blockade and SGLT2 inhibitors affect both proteinuria and filtration and must remain visible when comparing studies conducted in different treatment eras. [2] [5]

Randomized Phase 2b versus extension

ORIGIN Phase 2b randomized 116 participants across weekly 25, 75 or 150 mg atacicept and placebo. The prespecified pooled 75/150 mg comparison showed 25% relative proteinuria reduction versus placebo at week 24 and 35% at week 36. The week-36 eGFR comparison favored active treatment by approximately 5.7 mL/min/1.73m². The extension exposed 113 participants to atacicept, with 102 completing extension treatment. Analytical judgment: randomized eGFR support is useful but a small short-duration comparison is vulnerable to baseline variation. Later open-label stabilization is supportive durability evidence, not a continued placebo-controlled estimate, because previous placebo recipients crossed to drug and continuing participants were selected survivors. Extension and blinded-period denominators must not be interchanged. [2] [3]

ORIGIN 3 interim clinical evidence

The FDA review identifies the first 203 randomized and dosed participants in the interim set: 106 assigned atacicept and 97 placebo. Reported week-36 proteinuria reductions were 46% and 7%, with a model-based 42% relative reduction versus placebo, p<0.0001. The relative effect is not obtained by subtracting forty-six and seven percentage points. Analytical judgment: a ratio-based analysis of a skewed biomarker asks a different statistical question from an arithmetic difference in raw urine values. The full randomized population and the interim subset should be distinguished, as should model contributors and everyone dosed. Strong proteinuria separation raises the plausibility of kidney benefit but leaves open its magnitude, duration and sensitivity to missing eGFR measurements. [1] [4] [6]

Earlier eGFR analysis and estimands

Vera announced FDA alignment in June 2026 to bring the ORIGIN 3 eGFR analysis forward to the third quarter of 2026, with a possible subsequent supplemental application. The company's announcement does not disclose every revised statistical detail. Analytical judgment: evaluate the prespecified total and chronic eGFR slopes, follow-up distribution, acute changes, confidence intervals and handling of rescue or discontinued treatment. An early hemodynamic shift can alter a total slope without implying sustained structural benefit, while a chronic slope omitting early observations answers a narrower question. The assessment should also report how much information comes from participants with longer follow-up. A regulatory agreement to analyze sooner is not advance confirmation that the effect will be positive or sufficient for full approval. [4] [5]

Immunoglobulin suppression and durability

BAFF/APRIL inhibition requires attention to immunoglobulin concentrations and infection alongside injection tolerability. The Phase 2 publication described a safety profile similar to placebo, while extension observations add exposure without a persistent untreated comparison. Analytical judgment: a reduction in pathogenic antibody can coexist with a reduction in protective immunity, so aggregate adverse-event similarity should be supplemented by serious infection, low-IgG thresholds, treatment interruption and discontinuation. Kidney disease also changes baseline infection vulnerability. A favorable confirmatory result would combine slower eGFR loss with persistent proteinuria benefit and a manageable immune-safety burden. If eGFR is weak despite substantial proteinuria suppression, the discrepancy should be investigated using exposure, follow-up and missing-data analyses rather than dismissed as a statistical inconvenience. [2] [3] [4]

September 15: final kidney-function results

Vera reported the previously expected Q3 final ORIGIN 3 analysis on September 15. This clinical readout moves to History, separate from the July accelerated approval. The final analysis set is 428; the announcement does not allocate that set by arm or provide visit-specific analyzed N. It reports all prespecified endpoints met and plans a Q4 supplemental BLA. A plan to file is neither an accepted application nor full approval. [7]

What the final analysis adds, and what remains open

The prior proteinuria result remains preserved above. The new filtration and progression evidence addresses a more direct clinical question, but each endpoint has its own time scale: a week-52 change is not an annual slope through week 104. A 76% relative hazard reduction is not a 76-percentage-point absolute risk reduction. The small severe-outcome count is supportive and cannot independently establish a mortality benefit. [7]

The release identifies hierarchical testing for proteinuria, Gd-IgA1 and hematuria, but does not reproduce the revised full testing sequence, estimand, missing-data handling or exact composite definition. Those should be checked in the final presentation and analysis plan before treating every component as independently confirmed. No equal arm allocation is assumed from the aggregate final N.

Final-analysis safety is not the older label dataset

The announcement describes similar overall adverse-event and infection rates and reports no opportunistic infections or clinically relevant hypogammaglobulinemia. It does not supply final-analysis group totals for TEAE, SAE, deaths or adverse-event discontinuations. The 32% versus 28% infection figures in its prescribing-information section belong to the labeled dataset, not an explicitly identified week-104 safety analysis; they are not substituted into the new results table. [7]

Sources / References

1. Vera Q2 2026 Form 10-Q: approval and final analysis
2. Lafayette et al.: randomized ORIGIN Phase 2b, Kidney International
3. ORIGIN open-label extension publication
4. FDA integrated review of atacicept, 2026
5. Vera June 2, 2026: revised eGFR analysis agreement
6. Vera SEC presentation: Phase 3 proteinuria
7. Vera · ORIGIN 3 final kidney-function analysis · September 15, 2026